---
title: "3SBIO plans to allocate 31.1425 million shares to Pfizer, netting approximately HKD 785 million"
description: "3SBIO announced that it has signed a licensing agreement with Pfizer, involving the PD-1/VEGF bispecific antibody (SSGJ-707). The agreement will take effect on July 24, 2025. Pfizer agrees to subscrib"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/249949092.md"
published_at: "2025-07-24T11:32:02.000Z"
---

# 3SBIO plans to allocate 31.1425 million shares to Pfizer, netting approximately HKD 785 million

> 3SBIO announced that it has signed a licensing agreement with Pfizer, involving the PD-1/VEGF bispecific antibody (SSGJ-707). The agreement will take effect on July 24, 2025. Pfizer agrees to subscribe for 31.1425 million shares at a price of HKD 25.2055 per share, raising approximately HKD 785 million, with the subscription price representing a discount of about 17.09% to the market closing price

According to the Zhitong Finance APP, 3SBIO (01530) announced that it has entered into a licensing agreement with Pfizer regarding the PD-1/VEGF bispecific antibody (SSGJ-707).

All conditions precedent specified in the licensing agreement have been fulfilled, and therefore, the licensing agreement will take effect from July 24, 2025.

On July 24, 2025 (after trading hours), the company entered into a subscription agreement with Pfizer, under which Pfizer conditionally agreed to subscribe, and the company conditionally agreed to issue and allot 31,142,500 subscription shares at a subscription price of HKD 25.2055 per share, totaling approximately HKD 785 million. The subscription price per share represents a discount of approximately 17.09% to the closing price of HKD 30.40 per share reported on the Stock Exchange on the date of the subscription agreement

### Related Stocks

- [01530.HK - 3SBIO](https://longbridge.com/en/quote/01530.HK.md)
- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study | Pfizer Inc. (PFE) is launching a new observational study in Taiwan to evaluate the effectiveness of its multiple myeloma | [Link](https://longbridge.com/en/news/276252273.md) |
| How PTC’s (PTC) New FlexPLM Win with SPG Shapes Its Intelligent PLM Investment Story | PTC announced that SPG Company selected its FlexPLM solution to modernize product lifecycle operations, enhancing data a | [Link](https://longbridge.com/en/news/276294946.md) |
| CICC Reaffirms Their Buy Rating on Suzhou Ribo Life Science Co., Ltd. Class H (6938) | In a report released yesterday, from CICC maintained a Buy rating on Suzhou Ribo Life Science Co., Ltd. Class H, with a  | [Link](https://longbridge.com/en/news/276199846.md) |
| Kratos Defense & Security Solutions Officer Sells Shares | Phillip D Carrai, President of the STC Division at Kratos Defense & Security Solutions, sold 6,500 shares of common stoc | [Link](https://longbridge.com/en/news/276398029.md) |
| FirstService: Capitalizing on Cyclical Dislocation with Durable Growth and Conservative 2026 Upside | William Blair analyst Stephen Sheldon has reiterated a Buy rating on FirstService (FSV) stock, citing confidence in the  | [Link](https://longbridge.com/en/news/276281132.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.